Novo Nordisk Spins a Web of Growth Stories as Shares Claw Back from 52-Week Lows

Novo Nordisk shares rise 13% in 30 days as hemophilia candidate Denecimig shows strong data, diabetes launches expand, and US Medicare GLP-1 Bridge program boosts obesity drug demand.

The Danish drugmaker is weaving together threads from multiple businesses to repair investor sentiment after a punishing year. Shares of Novo Nordisk closed on Friday at €43.32, having gained nearly 13% over the past 30 days — a welcome relief for a stock that still sits 29.5% below its 52-week high of €60.95 from July 2025. The 12-month decline stands at 27.3%, but the recent momentum places the stock 8.4% above its 50-day moving average of €39.61, signaling a shift in short-term dynamics.

The recovery is backed by a flurry of operational developments spanning hemophilia, diabetes, weight loss, and capital allocation. At the International Society on Thrombosis and Haemostasis (ISTH) congress in Paris, Novo Nordisk presented extended data from the FRONTIER4 phase-3 extension study for its hemophilia A candidate Denecimig. The study enrolled 426 patients from age one onward. Among adults, the estimated annualised bleeding rate was 0.75; in children it fell to 0.37 — both considered low in haemophilia care. More striking, 71% of adult participants and 89% of children required no treatment for bleeding during the observation period, which had a median follow-up of six months for adults and four for children.

The safety profile remained clean. Injection-site reactions occurred in just 2.0% of children and 1.8% of adults, and no neutralizing antibodies against the drug were detected — a critical factor for subcutaneous biologics seeking regulatory approval. Novo Nordisk submitted a marketing application for Denecimig to the US Food and Drug Administration as early as September 2025, and the Paris data bolsters that dossier.

Beyond haemophilia, the pipeline shows both progress and a setback. In the diabetes core, Novo Nordisk launched its once-weekly insulin Awiqli in India on 9 July 2026, the seventh market globally. The weekly dose costs roughly $2.74, slashing annual injections from 365 to 52. The Indian insulin market is projected to grow from $660.5 million in 2025 to $916.4 million by 2034, giving Novo Nordisk a foothold in a market with significant catch-up potential. Meanwhile, the company withdrew a phase 2 comparator study for the CagriSema injection device, a small hiccup in the obesity pipeline that is otherwise dominated by GLP-1 demand.

That demand is getting a structural boost from US policy. The Centers for Medicare & Medicaid Services launched its pilot “Medicare GLP-1 Bridge” programme on 1 July 2026, capping eligible beneficiaries’ monthly out-of-pocket costs at $50 through the end of 2027. A Gallup survey from July shows roughly 11% of US adults now use GLP-1 drugs for weight reduction. CVS Health expanded its support for these therapies in June, including participation in the Bridge programme, though its chief tempered expectations on 12 July, noting that broader insurance coverage would require lower prices and better evidence of long-term healthcare cost savings.

On the capital returns front, the buyback programme launched in February 2026 is gathering pace. Novo Nordisk plans to repurchase shares worth 15 billion Danish kroner. As of 3 July, it had bought back roughly 23 million B-shares at an average price of 270.32 kroner, representing a volume of about 6.2 billion kroner. Institutional activity was mixed in the first quarter: Equitable Trust slashed its position by 72.2%, while Kornitzer Capital Management reduced its stake by 35.1%.

Investors now look to the second-quarter results due in early August. Analysts at Berenberg expect Novo Nordisk may raise its full-year guidance, citing robust demand for weight-loss drugs and stabilisation in the global diabetes market. The stock’s relative strength index of 66 suggests fresh buying momentum without entering overbought territory — a technical backdrop that, combined with the operational newsflow, gives the recovery some breathing room. Yet with the share price still almost a third below its high, the question remains whether these diverse catalysts can sustain the rally beyond a short-term bounce.